Sol-Gel Technologies (4SG) Stock Overview
Together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
4SG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sol-Gel Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.40 |
| 52 Week High | US$37.80 |
| 52 Week Low | US$3.00 |
| Beta | 1.36 |
| 1 Month Change | 7.93% |
| 3 Month Change | 40.48% |
| 1 Year Change | 278.61% |
| 3 Year Change | -9.69% |
| 5 Year Change | -56.02% |
| Change since IPO | -60.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4SG | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.6% | 2.6% | 1.0% |
| 1Y | 278.6% | 12.5% | 15.0% |
Return vs Industry: 4SG exceeded the German Pharmaceuticals industry which returned 11.3% over the past year.
Return vs Market: 4SG exceeded the German Market which returned 14.2% over the past year.
Price Volatility
| 4SG volatility | |
|---|---|
| 4SG Average Weekly Movement | 14.5% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 4SG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4SG's weekly volatility has decreased from 24% to 15% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 34 | Mori Arkin | www.sol-gel.com |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd. Fundamentals Summary
| 4SG fundamental statistics | |
|---|---|
| Market cap | €100.19m |
| Earnings (TTM) | -€7.67m |
| Revenue (TTM) | €16.19m |
Is 4SG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4SG income statement (TTM) | |
|---|---|
| Revenue | US$18.97m |
| Cost of Revenue | US$24.42m |
| Gross Profit | -US$5.45m |
| Other Expenses | US$3.54m |
| Earnings | -US$8.99m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.23 |
| Gross Margin | -28.71% |
| Net Profit Margin | -47.37% |
| Debt/Equity Ratio | 0% |
How did 4SG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 23:25 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sol-Gel Technologies Ltd. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Nachman | BMO Capital Markets Equity Research |
| null null | BMO Capital Markets Equity Research |
| Donald Ellis | Citizens JMP Securities, LLC |